Former Senior Vice President and General Counsel · MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Brian Lynch

A named executive officer of MADRIGAL PHARMACEUTICALS in every fiscal year CompBrief holds from FY2019 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$4,250,806

Salary $380,109Stock awards $2,245,336

FY2023: $5,266,584

6th of 7 named executive officers at Madrigal Pharmaceuticals by FY2024 total.

7 named officers on file for MADRIGAL PHARMACEUTICALS, FY2024

Brian Lynch’s pay file — $29

  • 6 fiscal years of pay, line by line
  • 6 equity grants, each cited to its filing
  • MDGL’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how MADRIGAL PHARMACEUTICALS’s whole pay program stands against its peers

  • MADRIGAL PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on MDGL→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2025 (DEF 14A).

Free

Get Brian Lynch’s full pay file as a PDF — free

More than this page: up to 10 years of Brian’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Brian Lynch compensation by year

MADRIGAL PHARMACEUTICALS Summary Compensation Table · all 6 fiscal years held
In US dollars, as MADRIGAL PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020FY2021FY2022FY2023FY2024
Salary$358,602$425,417$445,333$467,604$501,590$380,109
Bonus$0$0$0$0$0$0
Stock awards$0$0$0$0$4,500,000$2,245,336
Option awards$3,506,859$3,749,840$2,731,200$3,994,400$0$833,280
Non-equity incentive$192,602$260,946$240,610$282,807$247,000$0
Pension and deferred compensation$0$0$0$0$0$0
All other$10,574$11,690$13,338$13,338$17,994$792,081
Total$4,068,568$4,447,893$3,430,481$4,758,149$5,266,584$4,250,806

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: MADRIGAL PHARMACEUTICALS, INC. DEF 14A filed April 29, 2025, accession 0001104659-25-041254, and prior-year filings. Open the filing on EDGAR.

How this page was built: the MADRIGAL PHARMACEUTICALS, INC. filed document, accession 0001104659-25-041254. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2025.

$4.1M
$4.4M
$3.4M
$4.8M
$5.3M
$4.3M
FY19
FY20
FY21
FY22
FY23
FY24
SalaryNon-equity incentiveStock awardsOption awardsAll other

MADRIGAL PHARMACEUTICALS’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Bill SiboldPresident and Chief Executive Officer$12,214,250
Mardi DierExecutive Vice President and Chief Financial Officer$8,751,912
Rebecca TaubSenior Scientific and Medical Advisor and Former President, Research & Development and Chief Medical Officer$5,967,206
Alex HowarthFormer Senior Vice President and Chief Financial Officer$5,242,872
Shannon KelleyExecutive Vice President and Chief Legal Counsel$4,673,764
Brian Lynch · this pageFormer Senior Vice President and General Counsel$4,250,806
Carole HuntsmanExecutive Vice President and Chief Commercial Officer$3,949,441

The full MADRIGAL PHARMACEUTICALS compensation record

free company brief

This page is one person within MADRIGAL PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the MADRIGAL PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are MADRIGAL PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Brian Lynch's compensation dossier · One-time report. No refunds.